Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Scott E. Kamholz M.D., Ph.D.
Of Counsel
Washington +1 202 662 5339 skamholz@cov.com Download V-card

Scott Kamholz has scored major wins for clients in PTAB cases involving blockbuster life science technologies. He combines his experience as an Administrative Patent Judge and background in medicine, biophysics, and engineering to advise clients in the life sciences sector on a variety of complex patent litigation matters and PTAB proceedings. He has handled dozens of PTAB proceedings since returning to private practice.


  • Currently counsel of record in 12 AIA proceedings before the PTAB.
  • Lead Counsel for General Electric Company as patent owner in multiple IPR proceedings filed by Toyota Motor Corporation. The patents concern hybrid car technology.
  • Lead Counsel for University of Chicago as patent owner in a PGR filed by Genome & Company. The patent concerns co-administration of an immune checkpoint inhibitor and a bacterial formulation including bifidobacterial.
  • Counsel for Hoffmann-La Roche, Inc. as patent owner in an IPR challenging a patent concerning immunoglobulin production.
  • Lead Counsel for Huawei as petitioner in an IPR filed against a patent concerning wireless communication technology. The IPR was instituted in October 2018.
  • Represented Genentech, Inc. as patent owner in an IPR challenging a patent concerning AVASTIN® cancer therapy. The PTAB denied institution in August 2018.
  • Advised Eli Lilly and Company as petitioner in an IPR filed against a patent owned by the Trustees of the University of Pennsylvania allegedly covering Lilly’s ERBITUX® cancer therapy. The PTAB found all challenged claims unpatentable, a decision summarily affirmed by the Federal Circuit on appeal in September 2018.
  • Advised Bristol-Myers Squibb Company as patent owner in an IPR brought by Momenta Pharmaceuticals, Inc., challenging a patent concerning ORENCIA® rheumatoid arthritis therapy. The PTAB rejected petitioner’s challenge and confirmed the patentability of all challenged claims. The Federal Circuit dismissed Momenta’s appeal for lack of standing and mootness in February 2019.
  • Represented AstraZeneca as patent owner in an IPR challenging a patent concerning SYMBICORT® asthma and COPD therapy. The PTAB denied institution in July 2017
  • Counsel of Record for Pharmaceutical Research and Manufacturers of America (PhRMA) in numerous amicus briefs before the Supreme Court of the United States and the Court of Appeals for the Federal Circuit.

Memberships and Affiliations

  • American Intellectual Property Law Association, Member
  • Boston Intellectual Property Law Association, Member

Previous Experience

  • U. S. Patent Trial and Appeal Board (PTAB), Administrative Patent Judge